Travere Therapeutics (NASDAQ:TVTX) posted a profit for the first quarter on Monday.

The company reported quarterly earnings of 5 cents per share which beat the analyst consensus estimate of losses of 26 cents per share. The company reported quarterly sales of $127.199 million which missed the analyst consensus estimate of $136.822 million.

“This has been a transformative start to the year for Travere, highlighted by the landmark approval of FILSPARI in FSGS, record demand that reinforces FILSPARI’s foundational position in IgAN, and the advancement of pegtibatinase with the first new patient dosed in the restarted Phase 3 HARMONY study,” said Eric Dube, Ph.D., president and chief executive officer of Travere Therapeutics. “With FILSPARI now positioned to help more than 100,000 patients across IgAN and FSGS, we see a substantial and durable growth opportunity ahead, supporting a compelling long-term trajectory for the Company.”

Travere Therapeutics shares fell 1.1% to trade at $44.44 on Tuesday.

These analysts made changes to their price targets on Travere Therapeutics following earnings announcement.

  • HC Wainwright & Co. analyst Joseph Pantginis maintained the stock with a Buy and raised the price target from $47 to $57.
  • Wedbush analyst Laura Chico maintained the stock with an Outperform rating and raised the price target from $53 to $55.
  • Citigroup analyst Yigal Nochomovitz maintained Travere Therapeutics with a Buy and raised the price target from $53 to $59.
  • TD Cowen analyst Tyler Van Buren maintained the stock with a Buy and raised the price target from $45 to $60.

Considering buying TVTX stock? Here’s what analysts think:

Photo via Shutterstock